Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -42.15% is 12% above its 5-year average of -47.93%, near the high end of its 5-year range (-72.07%–-34.14%).
16.04% above its 12-month average of -50.20%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.97%.
RETURN ON ASSETS (ROA)
-42.15%
RETURN ON ASSETS (ROA) AVG TTM
-50.20%
RETURN ON ASSETS (ROA) AVG 3Y
-44.84%
RETURN ON ASSETS (ROA) AVG 5Y
-47.93%
RETURN ON ASSETS (ROA) AVG 10Y
-52.47%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.04%
CURRENT VS 3Y AVG
+6.00%
CURRENT VS 5Y AVG
+12.07%
CURRENT VS 10Y AVG
+19.68%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 717 covered companies
CURRENT VS SECTOR MEDIAN
-37.30%
vs the sector median at left
Aclaris Therapeutics, Inc.
Market Cap
$554.42M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$554.29M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$554.85M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$560.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$542.04M
Return on Assets (ROA)
-30.29%
TTM Avg
-86.87%
3Y Avg
-85.61%
5Y Avg
-77.02%
Market Cap
$566.81M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$541.30M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$569.16M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$536.32M
Return on Assets (ROA)
-34.82%
TTM Avg
-17.21%
3Y Avg
-15.93%
5Y Avg
-60.12%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $554.42M | -42.15% | -50.20% | -44.84% | -47.93% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.29M | -37.16% | -32.95% | -32.95% | -32.95% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $554.85M | -124.45% | -92.75% | -98.77% | -98.11% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.04M | -30.29% | -86.87% | -85.61% | -77.02% |
| CorMedix Inc. (CRMD)vs › | $566.81M | 20.70% | 2.32% | -24.93% | -30.88% |
| Delcath Systems, Inc. (DCTH)vs › | $541.30M | 0.39% | -16.14% | -90.03% | -84.55% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.16M | -20.89% | 7.49% | -5.84% | -12.60% |
| ProKidney Corp. (PROK)vs › | $536.32M | -34.82% | -17.21% | -15.93% | -60.12% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -59.22% | -47.88% | -51.20% | -67.88% |
ROA
-42.1%
ROE
-60.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -40.46% |
| 2024-12-31 | -59.94% |
| 2023-12-31 | -44.82% |
| 2022-12-31 | -34.14% |
| 2021-12-31 | -36.17% |
| 2020-12-31 | -72.07% |
| 2019-12-31 | -164.15% |
| 2018-12-31 | -48.17% |
| 2017-12-31 | -28.14% |
| 2016-12-31 | -27.30% |
| 2015-12-31 | -21.86% |
| 2014-12-31 | -49.01% |
| 2013-12-31 | -36.86% |
